Grant: Project Grant
McMaster University
$100,000.00
Exploring the role of extravascular factor IX in hemostasis in hemophilia B
EF 2022-23
Résumé
Clotting factors are proteins found in the blood that react to blood vessel damage to form a clot and prevent blood loss. If these clotting factors are not present or are defective, bleeding can occur. Severe hemophilia B (HB) is a bleeding disorder caused by insufficient activity of factor IX (FIX) and it is characterized by recurrent spontaneous bleeding, mainly in the musculoskeletal system. Replacement of the missing clotting factor (FIX) to maintain factor level >1% of normal by repeated intravenous injections is the main therapeutic approach. The measurable level of FIX in the blood of HB patients treated with the missing factor has long been considered the only determinant of the bleeding risk. The measurable FIX activity in the blood after the FIX infusions however could be only part of the total FIX present in the body at any given time and thus only partially explaining the protection from bleeding.
Indeed, there is evidence that there is an extensive reservoir of FIX localized in the various organs and tissues. In particular, it appears that FIX can migrate outside the blood compartment and bind to collagen, a very common protein in the connective tissue that supports the structure of the skin, tendon, vessels, muscle, and other organs and tissues. We have obtained preliminary data showing that this specific localization of FIX could be important for the prevention of bleeding episodes.
This might be relevant for the treatment of HB patients, especially now that there are several new FIX products available for the treatment of hemophilia. Some of these have been modified in a way that prevents them to migrate to the extravascular space, thus losing the ability to bind collagen.
This study aims to investigate the function of FIX in the tissues to improve the therapeutic management of hemophilia B patients.
Programme
Project Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
477302
Name
Matino Davide
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Hematology, Digestive Disease & Kidney
Projecttitle
Exploring the role of extravascular factor IX in hemostasis in hemophilia B
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Coagulation; Factor Ix; Hemophilia B
Abstract
Clotting factors are proteins found in the blood that react to blood vessel damage to form a clot and prevent blood loss. If these clotting factors are not present or are defective, bleeding can occur. Severe hemophilia B (HB) is a bleeding disorder caused by insufficient activity of factor IX (FIX) and it is characterized by recurrent spontaneous bleeding, mainly in the musculoskeletal system. Replacement of the missing clotting factor (FIX) to maintain factor level >1% of normal by repeated intravenous injections is the main therapeutic approach. The measurable level of FIX in the blood of HB patients treated with the missing factor has long been considered the only determinant of the bleeding risk. The measurable FIX activity in the blood after the FIX infusions however could be only part of the total FIX present in the body at any given time and thus only partially explaining the protection from bleeding.
Indeed, there is evidence that there is an extensive reservoir of FIX localized in the various organs and tissues. In particular, it appears that FIX can migrate outside the blood compartment and bind to collagen, a very common protein in the connective tissue that supports the structure of the skin, tendon, vessels, muscle, and other organs and tissues. We have obtained preliminary data showing that this specific localization of FIX could be important for the prevention of bleeding episodes.
This might be relevant for the treatment of HB patients, especially now that there are several new FIX products available for the treatment of hemophilia. Some of these have been modified in a way that prevents them to migrate to the extravascular space, thus losing the ability to bind collagen.
This study aims to investigate the function of FIX in the tissues to improve the therapeutic management of hemophilia B patients.
Competitiondate
202210
Approvedterm2
1 yr 0 mth
Pinamesdelim
Matino, Davide
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~